Vivacelle Bio's VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

/PRNewswire/ -- Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic...

Related Keywords

United States ,Kansas ,Kansas City ,Harven Deshield ,Naval Medical Research Center ,School Of Medicine ,Prnewswire Vivacelle Bio Inc ,Us Army Medical Research ,Drug Administration ,Vivacelle Bio Inc ,Naval Advanced Medical Development ,Trauma Services ,Technology Enterprise Consortium ,Development Command ,Sosland Missouri Endowed Chair ,Chief Innovation Officer ,Vivacelle Bio ,Extracorporeal Membrane Oxygenation ,Medical Technology Enterprise Consortium ,Medical Research ,Nc ,